跳至主要内容
临床试验/NCT01456819
NCT01456819Unknown2 期

Phase II Efficacy Study of Intramuscular Autologous Bone Marrow Mononuclear Cells Plus Mesenchymal Stem Cell Implantation Versus Autologous Bone Marrow Mononuclear Cells Implantation Only in Patients With Chronic Critical Limb Ischemia

National University of Malaysia2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2011年3月1日最近更新:
适应症

试验速览

阶段
2 期
发起方
入组人数
50
试验地点
2
主要终点
Change in angiogenesis

研究概览

简要总结

This is a randomized and single blinded study aimed to compare the efficacy between intramuscular autologous bone marrow mononuclear cells plus mesenchymal stem cell implantation and intramuscular autologous bone marrow mononuclear cells implantation only in patients with chronic critical limb ischemia. Patients will be randomized into two groups of equal number; patients in one group will be implanted with mononuclear cells and mesenchymal stem cells, and the other implanted with mononuclear cells only in the area of affected limb.

详细描述

When the long blood vessels supplying blood to the arms and legs become blocked (ischemic), patient will experience painful sensations in their calves when they walked which slowly become excruciating painful at rest. When the condition worsens, the patients will not be able to feel any pain from their legs and they will not know if there are any small ulcers or cuts on their legs. As a result, a small ulcer which goes unnoticed becomes bigger and can sometimes become infected. In the worst situations, infection might lead towards gangrene and septicaemia. Severe rest pain and/or ulcerations of ischemic limbs are defined as the state of chronic critical limb ischemia and at this point, amputation of the affected limb is suggested.

Conventional treatments include angioplasty/bypass operation to remove blood vessel blockage to restore blood supply, the use of prescribed medicines to aid in ulcer recovery and clear infection and debridement of damaged/infected tissue. Some procedures have to be performed multiple times. Amputation is inevitable in many cases because some blood capillaries cannot be corrected and restenosis of vessels is very common. Cell therapy with mononuclear cells and mesenchymal stem cells from bone marrow is promising because these stem cells are capable of stimulating and regenerating capillaries and blood vessels.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of critical limb ischemia leading to ischemic ulcers in which amputation is indicated
  • Not suitable for, or remain symptomatic despite angioplasty, bypass operation or collateralization

排除标准

  • Contraindication to epidural anesthesia and bone marrow aspiration
  • Contraindication to contrast angiography
  • Evidence of neoplasia and bone marrow diseases
  • Any acute or chronic communicable diseases including Hepatitis B, Hepatitis C and HIV
  • Patients with a limited life expectancy (< 1 year)
  • Patients with myocardial infarction or stroke within 6 months
  • Patients with coronary intervention within 6 months
  • Renal impairment indicated by serum creatinine greater than two times upper limit of the normal range
  • Liver impairment indicated by serum aspartate transaminase and alanine transaminase greater than two times upper limit of normal
  • Any other co-morbidity which the physician deems as a contraindication to stem cell transplantation

结局指标

主要结局

Change in angiogenesis

时间窗: 1 month, 3 months, 6 months, 9 months, 12 months

Measurement of angiogenesis by presence of peripheral pulses, capillary refill and transcutaneous oxygen saturation (TCOS).

次要结局

  • Visual Analog Score(1 month, 3 months, 6 months, 9 months, 12 months)
  • Change in ulcer size(1 month, 3 months, 6 months, 9 months, 12 months)
  • Exercise Treadmill Test(1 month, 3 months, 6 months, 9 months, 12 months)
  • Improvement in vascularity and blood supply(1 month, 3 months, 6 months, 9 months and 12 months)

研究者

发起方
National University of Malaysia
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr Hanafiah Harunarashid

Senior Consultant Vascular Surgeon

National University of Malaysia

研究点 (2)

Loading locations...

相似试验